CTAP101 30 μg capsules

DRUG2 trials

Sponsors

OPKO IP Holdings II, Inc.

Conditions

Chronic Kidney DiseaseHyperparathyroidism, SecondaryVitamin D Deficiency

Phase 3

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

CompletedNCT01651000

OPKO IP Holdings II, Inc.Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency

Start: 2012-09-30End: 2014-07-31Updated: 2025-01-13

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

CompletedNCT01704079

OPKO IP Holdings II, Inc.Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency

Start: 2012-11-30End: 2014-09-30Updated: 2025-01-13